SOUTH SAN FRANCISCO, Calif.
April 12, 2013
, a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of
Shelly D. Guyer
as chief financial officer.
"We are delighted to welcome
to the Veracyte team," said
, Veracyte's cofounder and chief executive officer. "Her extensive background in the life science and finance industries will be critical as we experience strong growth of our first product, the Afirma® Thyroid FNA Analysis, and as we expand our molecular cytology platform to other clinical areas to similarly help reduce unnecessary surgeries and lower healthcare costs." Ms. Anderson noted that data published in the
New England Journal of Medicine
suggest that Veracyte's genomic test for improved thyroid cancer diagnosis can potentially help tens of thousands of patients each year in
the United States
avoid thyroid surgery.
Ms. Guyer previously was chief financial officer and executive vice president of finance and administration at iRhythm Technologies, a private, venture-backed medical device and services company. Prior to that, she served on the management team and as vice president of business development and investor relations at Nuvelo, a public biotechnology company. Ms. Guyer began her business career at J.P. Morgan Securities and its predecessor companies, where for over 17 years she held various positions, including principal and vice president of health care banking for the West Coast, leading financings for a variety of large and small cap life science companies.
"I am pleased to join the talented management team at Veracyte," said Ms. Guyer. "The company's mission of helping patients avoid surgery is compelling. Additionally, with the introduction of its first product, the Afirma Thyroid FNA Analysis, Veracyte has set a new standard for launching a molecular diagnostics product successfully, quickly and cost-efficiently. I look forward to helping the company build on its success to date."